Search - tctmd.com

Displaying 281 - 300 of 1423

Sort: Relevancy | Date

Presentation TCT 2017

Registry Update: ABSORB UK

Presenter: Stephen G. Ellis, Takeshi Kimura, Mark A. de Belder

October 31, 2017

Presentation TCT 2017

The Combo Stent: From Concept to Clinical Performance

Presenter: Manel Sabate, Joanna J. Wykrzykowska, Roxana Mehran

October 31, 2017

Presentation TCT 2017

PORTICO TAVR Technology Review and Clinical Program Updates

Presenter: Gregory P. Fontana

October 31, 2017

Presentation TCT 2017

Registry Update: ABSORB Extend At 3 Years

Presenter: Stephen G. Ellis, Takeshi Kimura, Antonio L. Bartorelli

October 31, 2017

Presentation TCT 2017

ACURATE Neo TAVR Technology Review and Clinical Program Updates

Presenter: Thomas Walther

October 31, 2017

Presentation TCT 2017

What Is the Optimal DAPT Duration With ABSORB? Results From a Comprehensive Meta-Analysis

Presenter: Azeem Latib, Gregg W. Stone

October 31, 2017

Presentation TCT 2017

ABSORB IV 30-Day Results: Is Improved Technique Reflected in Superior Early Outcomes?

Presenter: Azeem Latib, Dean J. Kereiakes

October 31, 2017

Presentation TCT 2017

LOTUS TAVR Technology Review (Including EDGE) and Clinical Program Updates

Presenter: Michael J. Reardon

October 31, 2017

Presentation TCT 2017

Featured Lecture: ABSORB Program 3-Year Meta-Analysis and Adjusted PSP Evaluation - Lessons Learned With a First Generation Scaffold

Presenter: Azeem Latib, Gregg W. Stone

October 31, 2017

Presentation TCT 2017

Valve Degeneration and Leaflet Mobility Considerations: Assessing Clinical Relevance

Presenter: Martin B. Leon, Changfu Wu, Lars Sondergaard

October 31, 2017

Presentation TCT 2017

Outcomes and Clinical Implications From EXPLORE

Presenter: Barry D. Rutherford, Robert W. Yeh, Jose P.S. Henriques

October 31, 2017

Presentation TCT 2017

EVOLUT R TAVR Technology Review (Including EVOLUT 34mm and PRO) and Clinical Program Updates

Presenter: John K. Forrest

October 31, 2017

Presentation TCT 2017

ABSORB II at 4 Years: Clinical Outcomes Beyond the Cusp of Complete Bioresorption

Presenter: Azeem Latib, Bernard R. Chevalier

October 31, 2017

Presentation TCT 2017

Outcomes and Clinical Implications From the Euro-CTO Trial

Presenter: Barry D. Rutherford, Robert W. Yeh, Gerald S. Werner

October 31, 2017

Presentation TCT 2017

ABSORB in STEMI I: TROFI II 3-Year Clinical Outcomes and Correlations With the 6-Month OCT Findings

Presenter: Azeem Latib, Manel Sabate

October 31, 2017

Presentation TCT 2017

SAPIEN 3 TAVR Technology Review (Including Sapien 3 ULTRA) and Clinical Program Updates

Presenter: John G. Webb

October 31, 2017

Presentation TCT 2017

Outcomes and Clinical Implications From DECISION-CTO

Presenter: Barry D. Rutherford, Robert W. Yeh, Seung-Whan Lee

October 31, 2017

Presentation TCT 2017

New Insights From AIDA: Subgroups and Predictors of Adverse Events

Presenter: Azeem Latib, Joanna J. Wykrzykowska

October 31, 2017

News Conference News TCT 2017

Intermediate-Risk TAVR Substantially More Cost-effective Than Surgery

Yael L. Maxwell

October 31, 2017

Presentation TCT 2017

TCT 32: Why Does Exercise in Cold Air Increase Susceptibility to Myocardial Ischaemia?

Presenter: Justin E. Davies, Bernard De Bruyne, Rupert Williams, MD

October 31, 2017

Advertisement

Registry Update: ABSORB UK

The Combo Stent: From Concept to Clinical Performance

PORTICO TAVR Technology Review and Clinical Program Updates

Registry Update: ABSORB Extend At 3 Years

ACURATE Neo TAVR Technology Review and Clinical Program Updates

What Is the Optimal DAPT Duration With ABSORB? Results From a Comprehensive Meta-Analysis

ABSORB IV 30-Day Results: Is Improved Technique Reflected in Superior Early Outcomes?

LOTUS TAVR Technology Review (Including EDGE) and Clinical Program Updates

Featured Lecture: ABSORB Program 3-Year Meta-Analysis and Adjusted PSP Evaluation - Lessons Learned With a First Generation Scaffold

Valve Degeneration and Leaflet Mobility Considerations: Assessing Clinical Relevance

Outcomes and Clinical Implications From EXPLORE

EVOLUT R TAVR Technology Review (Including EVOLUT 34mm and PRO) and Clinical Program Updates

ABSORB II at 4 Years: Clinical Outcomes Beyond the Cusp of Complete Bioresorption

Outcomes and Clinical Implications From the Euro-CTO Trial

ABSORB in STEMI I: TROFI II 3-Year Clinical Outcomes and Correlations With the 6-Month OCT Findings

SAPIEN 3 TAVR Technology Review (Including Sapien 3 ULTRA) and Clinical Program Updates

Outcomes and Clinical Implications From DECISION-CTO

New Insights From AIDA: Subgroups and Predictors of Adverse Events

Intermediate-Risk TAVR Substantially More Cost-effective Than Surgery

TCT 32: Why Does Exercise in Cold Air Increase Susceptibility to Myocardial Ischaemia?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content